The stock plunged over 5% on media reports that the US-based
Ohm Laboratories-the company's facility in the US, is under the
surveillance of the USFDA. In another set-back to the company, its
US-based subsidiary Ranbaxy Laboratories Inc., received a
Paragraph IV certification notice of filing from Watson Laboratories
Inc. of an Abbreviated New Drug Application to the USFDA.